Fig. 3: PIM447 reduces the proliferation, viability and G1/S transition of cells with JAK/STAT pathway mutations.

Cell growth (a) and viability (b) assays of M07e (left) and Ba/F3 cells (right) transduced with JAK3^Q988P, JAK1^V658F or STAT5^N642H, treated with PIM447 (0.1 μM, 1 μM or 10 μM) and referred to untreated cells. Jurkat cells were used as a negative control since they lack oncogenic JAK/STAT pathway mutations and PIM1 overexpression. Statistical comparisons are made against untreated cells. c Cell proliferation analysis of M07e (left) and Ba/F3 cells (right) transduced with JAK3^Q988P, JAK1^V658F or STAT5^N642H, treated with PIM447 (1 μM) and referred to untreated cells. Statistical comparisons are made against Jurkat cells. d Representative images for M07e cells transduced with JAK3^Q988P are depicted. e Cell cycle analysis of M07e (left) and Ba/F3 cells (right) transduced with JAK3^Q988P, JAK1^V658F or STAT5^N642H, treated with PIM447 (1 μM) and referred to untreated cells. Statistical comparisons are made against Jurkat cells. f Representative images for M07e cells transduced with JAK3^Q988P are depicted. g Western blot for CyclinD2 in M07e (left) and Ba/F3 cells (right) transduced with JAK3^Q988P, JAK1^V658F or STAT5^N642H and treated with PIM447 (1 μM) or left untreated. The graphics show the mean ± standard deviation (s.d.) after three independent experiments. All images are representative examples of at least three independent experiments.